home  versant ventures search for versant ventures on linkedin share lp access contact us careers ive built two companies with versant ventures and value their distinctive investment approach they have a clear understanding of the recipe for startup company success and represent a premium brand in healthcare venture capital today david clapper  minerva surgical versant invested in life the people at versant understand the entrepreneurial process they take a longterm view of the portfolio company and help provide perspective and support in times thick and thin amar sawhney  ocular therapeutix versant invested in life versant has been and continues to be a superb investor they provide insight and counsel to our efforts and their willingness to roll up their sleeves to problem solve with us has been invaluable michael d clayman md  flexion therapeutics versant invested in life featured case study biotechnology quanticel pharmaceuticals quanticel technology is based on the work of stanford researchers and company founders stephen quake and michael clarke versant had backed other genomic technologies invented by quake and moved quickly to incubate quanticel in  shortly after the company was founded the idea behind quanticel’s singlecell genomic analysis technology is to unlock the mystery of cancer drug resistance through the analysis of tumor cell heterogeneity as a tumor grows and cancer cells rapidly replicate the genetic diversity of these cells increases full quanticel pharmaceuticals case study news highlights venatorx pharmaceuticals raises  million series b venatorxfinal repare therapeutics raises us million series a repare therapeutics raises us million series a crispr therapeutics announces the appointment of jon terrett phd to head of immunooncology research and translation crispr appoints jon terrett versant ventures launches jecure therapeutics jecureseriesa versant overview  versant ventures search for versant ventures on linkedin share lp access contact us careers propelling life sciences companies versant ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies the firm invests across the healthcare sector and at all stages of company development with an emphasis on the discovery and development of novel therapeutics with  billion under management and offices in north america and europe versant has built a team with deep investment operating and scientific expertise that enables a handson approach to company building since the firm’s founding in  nearly  versant companies have achieved successful acquisitions or ipos versant in europe versant ventures has a team in basel switzerland dedicated to working with entrepreneurs industry and leading academics across europe the team has decades of experience in the pharmaceutical and biotechnology industries including global roles in drug discovery research and product development for companies such as roche novartis and lilly versant’s basel office is led by tom woiwode guido magni and gianni gromo   contact us  versant ventures search for versant ventures on linkedin share lp access contact us careers contact us at one of our five offices san francisco one sansome suite  san francisco ca  phone   fax   new york  west st street suite  new york ny  phone   minneapolis  equitable drive suite  eden prairie mn  phone   basel switzerland versant ventures switzerland gmbh aeschenvorstadt  ch basel switzerland phone      canada versant ventures canada limited  great northern way suite  vancouver bc vt t phone   medical devices archives  versant ventures search for versant ventures on linkedin share lp access contact us careers medical devices ebb therapeutics oakmont pa ebb is developing a therapeutic device for insomnia inari medical irvine ca inari medical is a medical device company pioneering innovative devices for the interventional treatment of vascular thrombi and emboli metavention minneapolis mn metavention is developing novel interventional therapies for type  diabetes sebacia duluth ga sebacia is developing a medical device to cure acne zyga technology minneapolis mn zyga is developing and marketing innovative minimally invasive surgical solutions to treat conditions of the spine rox medical san clemente ca rox is developing devices for treatment of diseases of the respiratory system respicardia minnetonka mn respicardia is developing an implantable system to treat central sleep apnea in patients with heart failure orametrix richardson tx orametrix is a leading industry provider of innovative d technology solutions facilitating and improving the quality of orthodontic care neurotech pharmaceuticals lincoln ri neurotech pharmaceuticals is pioneering encapsulated cell technology as a drug delivery platform for retinal degenerative diseases minerva surgical cupertino ca minerva is developing next–generation technology for treating excessive menstrual bleeding microfabrica van nuys ca microfabrica has developed a broad microscale platform for minimally invasive procedures and for complex dynamic implants intuity medical sunnyvale ca intuity medical formerly rosedale is developing a handheld all inone discrete bloodbased diagnostic platform that will enhance glucose monitoring for diabetic patients holaira plymouth mn novel devices to treat obstructive lung disease  previously innovative pulmonary solutions halscion suwanee ga halscion is advancing a solution for reduction of surgically induced scarring forsight vision  menlo park ca forsight vision is evaluating a variety of technologies to address important unmet patient needs in key ophthalmic markets forsight vision  menlo park ca forsight vision  inc is developing novel ocular drug delivery technologies ceterix orthopedics fka suturepro technologies inc menlo park ca ceterix is developing a new orthopedic suturing technology that is focused on improving easeofuse and operative speed celula san diego ca celula is developing rare cell isolation technology for diagnostic and therapeutic purposes benvenue medical santa clara ca benvenue medical is developing and marketing innovative spine repair technology alterg fremont ca alterg is marketing its “gtrainer” technology a treadmill system that reduces the users’ body weightimpact of running and thereby enhances physical rehabilitation from orthopedic or neurological injury acufocus irvine ca acufocus is developing a corneal implant to treat presbyopia the need for reading glasses portfolio companiesbiotechnology biotechnology exits  ipos medical devices medical device exits  ipos additional investments additional investment exits discovery engines case studies amira pharmaceuticals inception  inc quanticel pharmaceuticals insider trading  versant venture capital iv lp  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  versant venture capital iv lp select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in common stock purchase or sale transactiondate reporteddate company symbol insiderrelationship sharestraded averageprice totalamount sharesowned filing purchasea  pm crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner    indirect view a indicate amendment filing stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view conversion  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant affiliates fund v lpversant ophthalmic affiliates i lpversant venture capital v canada lp owner   indirect view option award  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant venture capital v canada lp owner   indirect view option award  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant venture capital v canada lp owner   indirect view option award  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant venture capital v canada lp owner   indirect view option award  pm nana crispr therapeutics ag crsp versant venture capital iv lpversant side fund iv lpversant venture capital v lpversant venture capital v canada lp owner   indirect view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  versant venture capital iv lp private company information  bloomberg july    am et capital markets company overview of versant venture capital iv lp snapshot people company overview versant venture capital iv lp specializes in early stage seed and later stage investments the fund seeks to invest in the healthcare sector with a focus on early stage medical device biotech and pharmaceutical companies versant venture capital iv lp is comprised of versant side fund iv lp one sansome streetsuite san francisco ca united statesfounded in  phone  fax  key executives for versant venture capital iv lp mr ross a jaffe md md and partner age  mr brian g atwood veracyte cofounder  md age  mr samuel d colella mba managing director age  mr william j link phd cofounder  md age  ms rebecca b robertson managing director compensation as of fiscal year  similar private companies by industry company name region visory llc united states  road partners llc united states t partners llc united states jumpcom inc united states  ontario inc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact versant venture capital iv lp please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close portfolio overview  versant ventures search for versant ventures on linkedin share lp access contact us careers partnering to improve healthcare we are proud of our track record of working with extraordinary scientists entrepreneurs and business leaders to build transformational companies that impact and improve healthcare we invest our time talent leadership and expertise in all our portfolio partnerships we pursue opportunities where we can add value through our handson collaborative approach and devote the appropriate mix of strategic advice domain expertise and capital to help accelerate their growth we invest in life and in success since our inception in  we have invested in over  seed early and growth stage companies – of which  have gone public or been acquired to date versant overview  versant ventures search for versant ventures on linkedin share lp access contact us careers propelling life sciences companies versant ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies the firm invests across the healthcare sector and at all stages of company development with an emphasis on the discovery and development of novel therapeutics with  billion under management and offices in north america and europe versant has built a team with deep investment operating and scientific expertise that enables a handson approach to company building since the firm’s founding in  nearly  versant companies have achieved successful acquisitions or ipos versant in europe versant ventures has a team in basel switzerland dedicated to working with entrepreneurs industry and leading academics across europe the team has decades of experience in the pharmaceutical and biotechnology industries including global roles in drug discovery research and product development for companies such as roche novartis and lilly versant’s basel office is led by tom woiwode guido magni and gianni gromo   william j link phd executive profile  biography  bloomberg july    am et capital markets company overview of versant venture management llc snapshotpeople  overviewboard memberscommittees executive profile william j link phdcofounder  md versant venture management llcagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr william j link also known as bill phd is the cofounder and managing director of versant venture management llc dr link cofounded versant venture management llc in  he specializes in early stage investing in medical devices he has extensive knowledge of medical devices particularly in ophthalmology and has contributed to versants recognized leadership in this specialty area  he is the founder and principal of flying l partners he served as  a general partner of brentwood venture capital where he invested in a number of early stage companies he founded chiron vision corporation in  and also served as its chairman and chief executive officer until  he founded and served as the president of american medical optics before entering the health care industry dr link was an assistant professor in the department of surgery at the indiana university school of medicine he has been the chairman of glaukos corporation since june  and aviana molecular technologies llc since june  he serves as chairman of forsight vision inc he serves as the chairman of alphaeon corporation and nexis vision inc he has been an independent director of edwards lifesciences corp since may   he has been an independent director of second sight medical products inc since  he has been a director of allegro ophthalmics llc since november   and truevision systems inc since june   he serves as a director of forsight vision and oculeve inc dr link serves as a director of forsight vision inc forsight vision inc and neurotech sa he serves as a director of neovista inc he serves as a director of sightlife surgical inc and acufocus inc he serves as a director of tearclear corp he served as a director of forsight labs llc and foresight vision inc his affiliations and activities includes founding member of american college of ophthalmic surgery cochair of blindness annual retinal innovation symposium cochair of blindness dining in the dark cochair of ophthalmology innovation summit  conference trustee of frederick n griffith foundation at tissue banks international and advisory board member of university of california irvine department of biomedical engineering he served as the chairman of neurotech pharmaceuticals inc until august  and serves as its director he served as chairman of merge cad inc neovista inc refractec llc and foresight vision inc he served as the chairman of intralase corp since july  and cameron health inc until may  he served as a director of inogen inc from  to february   and abbott medical optics inc formerly advanced medical optics inc from june  to february   he served as a director of ferx incorporated merge cad inc formerly confirma inc genyx lensx lasers inc intra therapeutics refractec llc and orametrix inc he served as a director of intralase corporation since december  and eyeonics inc since october  in february  he was named as engineer of the year by the orange county engineering council with more than  years of operations experience in the healthcare industry he has a proven record of building and operating large and successful medical product companies dr link holds phd ms and bs in mechanical engineering from purdue universityread full background corporate headquarters one sansome streetsan francisco california united statesphone fax  board members memberships directorneurotech pharmaceuticals incdirectoracufocus incdirectorneovista incchairmannexis vision incdirectorforsight vision incdirectoroculeve incchairmanalphaeon corporationdirectorforsight vision incdirectorsightlife surgical incdirectortearclear corppresentindependent directoredwards lifesciences corporationpresentchairmanaviana molecular technologies llcpresentdirectorallegro ophthalmics llcpresentdirectortruevision systems inc education ms purdue universityphd purdue universitybs purdue university other affiliations brentwood venture capitalmerge cad incferx incorporatedintralase corprefractec llcneurotech pharmaceuticals incorametrix incedwards lifesciences corporationabbott medical optics incglaukos corporationacufocus inccameron health incbrentwood associates ix lpversant venture capital ii lppurdue universityeyeonics incinogen incsecond sight medical products incneovista incversant venture capital iii lpforsight labs llcchiron vision corporationtruevision systems incnexis vision incversant venture capital iv lplensx lasers incforsight vision incoculeve incversant venture capital v lpaviana molecular technologies llcallegro ophthalmics llcalphaeon corporationforsight vision incsightlife surgical inctearclear corp annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact versant venture management llc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft biotechnology archives  versant ventures search for versant ventures on linkedin share lp access contact us careers biotechnology venatorx pharmaceuticals malvern pa venatorx is a developing nextgeneration antibiotics to treat multidrug resistant mdr infections vividion therapeutics san diego ca vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteomewide drug and target discovery repare therapeutics montreal canada repare is developing new precision oncology drugs for patients that target specific vulnerabilities of tumor cells northern biologics toronto canada northern biologics is developing novel therapeutic antibodies for the treatment of human diseases in oncology fibrosis and other diseases piqur therapeutics basel switzerland piqur is a swiss pharmaceutical company focusing on the discovery and development of innovative small molecule therapeutics based on lipid kinase pik and mtor inhibition for the treatment of cancer as well as other indications anokion ecublens switzerland anokion is focused on leveraging its proprietary immune tolerance technology to develop novel protein therapeutics and treatments for autoimmune diseases mosaic biomedicals barcelona spain mosaic biomedicals is a barcelonabased company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor’s immune system mosaic’s innovative treatments are derived from a deep understanding of the tumor biology and aim to offer safer and more effective options to cancer patients aavlife paris france aavlife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need inception ibd san diego ca inception ibd is focused on translating academic discoveries in the field of ibd into firstinclass small molecule drugs crispr therapeutics basel switzerland crispr therapeutics is making use of significant advances in the field of gene editing and focused on translating the crisprcas technology in truly transformational therapeutics for common and rare genetic diseases audentes therapeutics san francisco ca audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious rare diseases through the application of gene therapy technology gensight biologics tassin la demi lune  france gensight is a leading company in gene therapy specialized in prevention of loss of vision and restoration of sight inception  san diego ca inception  is focused on the discovery of therapeutics for sensorineural hearing loss  the company has entered into a partnership with roche with a prenegotiated acquisition at ind viral logic systems technology seattle wa vlst corp has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases theraclone sciences seattle wa theraclone sciences inc is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases acumen san francisco ca acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphoneenabled digital behavior evaluation improving outcomes for patients and simplifying care for specialists phaserx seattle wa phaserx is developing a novel approach to intracellular delivery of macromolecules inception  san diego ca inception  is focused on oncology the company is translating biological insights into novel firstinclass small molecule drugs for cll and other oncology indications spanning both liquid and solid tumors inception  san diego ca inception  is translating biological insights into novel firstinclass small molecule drugs to treat diseases of aging ruiyi shanghai china ruiyi is a drug discovery and development company focused on firstinclass antibodies targeting g protein coupled receptors gpcrs am ventures menlo park ca am ventures is a seedstage fund focused on creating and building biotech companies portfolio companiesbiotechnology biotechnology exits  ipos medical devices medical device exits  ipos additional investments additional investment exits discovery engines case studies amira pharmaceuticals inception  inc quanticel pharmaceuticals ﻿ company profile add company sign in with sign in with add company add event sign in with sign in with android iphone companies events company events message this company message the business message this company message the business post your social media updates network would you like businessvibes to send this message to similar companies in this industry profile visits prev visits  total  current  share and improve this company’s performance boost this company’s visibility by sharing it with your contacts about company financial details x receive updates from textiles companies in india for free receive updates from textiles companies in india for free   already a businessvibes member login what kind of updates will i receive latest business listings as they become available current trends that are making noise in your industry reports and articles about your market pushed directly to you you will also receive early access to the businessvibes mobile app access to full profiles can help you instantly contact businesses directly pursue and qualify leads for your business research and find business offerings that you seek you will also receive early access to the businessvibes mobile app x were glad that youre back simply login and unlock full profile easy one click login dont worry we never post without your permission         or         already an active user login with your email   forgot password new to businessvibes sign up x receive updates from textiles companies in india for free already in businessvibes login access to open trade requests can help you find products and services early less competition for trade requests more costeffective than traditional trade requests   top  venture capital firms of   the lists  gen genetic engineering  biotechnology news hcv drug therapy and the dna base excision repair system d hydrogels for tissuespecific cartilage repair gen quiz evaluate your knowledge on cancer obesity and crispr movies reducing the need for clinical bioequivalence endpoint studies is calcium the achilles heel for clostridium infections literature review organsonchips marching in pcr optimization  the prodrug opportunity making good drugs better exclusives looking at the cart landscape as first  hcv drug therapy and the dna base excision repair system d hydrogels for tissuespecific cartilage repair gen quiz evaluate your knowledge on cancer obesity and crispr movies reducing the need for clinical bioequivalence endpoint studies is calcium the achilles heel for clostridium infections literature review organsonchips marching in pcr optimization  the prodrug opportunity making good drugs better news stand up to cancer lustgarten foundatio  biomarkers may predict human lifespan chromemt created to visualize how cancer proteins lead to disease dna repair under the influence may raise risk of cancer cellbased therapies soften up cancer by targeting tumor stiffness jj bavarian nordic expand vaccine collaboration to hiv hepatitis b a gene fix for a mouse model of duchenne protein pair help transfer of chromosomes to the right daughter cell “pancreas in a dish” tells story of how metastatic cells turn back time the lists  takeover targets for  top  under  top  european biopharma clusters  biotech and biopharma recruiters top  immunooncology collaborations the top  bestselling drugs of   clinical failures of q  top eight asia biopharma clusters  top  us biopharma clusters magazine panasonic launches new dualcompressor f manufacturing of aav vectors for gene therapy insights gen roundup top trends in tissue engineering gene therapy a new twist on an old helix optimizing the delivery of peptidebased therapeutics short stories to peruse—with info you might use accelerating novel therapeutic discovery advancing d cell culture for biomedical research using primary cells current issue » past issues » more gen new products ebooks subscribe to gen podcasts events webinars polls best of the web best apps video bioperspectives subscribe gen select loginregister leading the way in life science technologies facebook twitter linkedin youtube google rss gen exclusives more » d hydrogels for tissuespecific cartilage repair stanford engineers successfully encapsulate cartilageforming chondrocytes and mesenchymal stem cells in d hydrogels biomarker platforms advance immunooncology improved cancer immunodiagnostics and immunotherapeutics depend on biomarker discovery pcr optimization  optimization of denaturation temperature can enhance pcr assays dna fab keeps getting more fab dna fabrication keeps improving thanks to innovations in biosensors dna nanoswitches and microfluidic chips the lists more » december   top  venture capital firms of  who are the big spenders that help grease the wheels of biotech alex philippidis this year’s list has been expanded to a top  in part to include the higher number of firms with funds totaling more than  billion compared with  bobby  fotoliacom just last week a new biotech company called juno therapeutics was launched to the tune of  million in series a financing where did this money come from from the generous coffers of venture capital firms including arch venture partners and the alaska permanent fund such it is with every startup—venture capital is part of what makes new biotechs and biopharmas blossom so which vc companies invested money in those fields this year below is a list of  top venture capital firms and broader financial firms that invest venture capital or other equity in early to latestage biotechnology and pharmaceutical companies ranked by total capital under management or for some firms total active “committed” capital from funds in use this year’s list has been expanded to a top  in order to paint a more complete picture of biopharma venture investment and its key players—as well as to include the higher number of firms with funds totaling more than  billion compared with  the firms themselves are the sources of much of the information though in some instances they have declined comment on news reports that they are raising additional capital those instances are included in footnotes where the companies have not challenged the accuracy of the reports in a handful of instances figures and facts came from biographies of the firms’ principals available on the websites of investee companies and publicly available investor presentations posted online interestingly this year five firms listed closed on new funds—less than the seven that did so last year but a stillsignificant sign that more firms resumed raising new capital following years of nearstandstill wrought by the – recession  enterprise partners venture capital city cities where offices are located la jolla ca fund size and status more than  billion under management across six funds current fund  million epvi closed  current biopharma portfolio companies ascenta therapeutics celladon celula complete genomics typical investment range initial investment more typically ranges between  million and  million with additional funds reserved for followon financings occasionally the partnership will invest as little as k in a seed stage venture preference for investing in californiabased businesses year established   delphi ventures city cities where offices are located menlo park ca fund size and status more than  billion in eight funds current fund  million delphi ventures viii closed  current biopharma portfolio companies alder biopharmaceuticals alexza pharmaceuticals calithera biosciences labcyte neuraxon oncomed pharmaceuticals proacta ptc therapeutics relypsa typical investment range investment size ranges from  to  million per company year established   abingworth city cities where offices are located london menlo park ca waltham ma fund size and status more than  billion under management across nine funds most recent fund name abingworth bioventures v expanded to £ million  million with the addition of £ million  million raised in december  the new monies were raised in an affiliated fund abingworth bioventures v coinvest growth equity fund firm also invests through abingworth bioequities an openended fund and abingworth’s first dedicated solely to investments in quoted stocks current biopharma portfolio companies ablynx algeta alnylam pharmaceuticals amarin avedro avila therapeutics avillon chiasma chroma therapeutics clovis oncology cytos biotechnology dicerna pharmceuticals effector therapeutics epigenomics evfthyroid gensight biologics hydra biosciences intellikine labcyte magellan biosciences md online pathwork diagnostics personalis portola pharmaceuticals primeradx prosensa sfj pharmaceuticals senseonics supernus pharmaceuticals valeritas zogenix typical investment range  million to  million per company monies may be invested over more than one round of financing investments across all stages of company development including early and latestage venture venture investments in public equities vipes growth equity and public markets year established   third rock ventures city cities where offices are located boston and san francisco fund size and status more than  billion raised in three funds current fund  million fund iii which closed in march and was created to help launch up to  new companies focused on “disruptive” areas of science and medicine current biopharma portfolio companies ablexis afferent pharmaceuticals agios pharmaceuticals alcresta allena pharmaceuticals alnara pharmaceuticals bluebirdbio blueprint medicines constellation pharmaceuticals cytomx therapeutics edimer eleven biotherapeutics ember therapeutics foundation medicine globalblood therapeutics igenica jouncetherapeutics kala pharmaceuticals lotus tissue repair myokardia panoptica rhythm pharmaceuticals sage therapeutics topica pharmaceuticals warpdrivebio zafgen typical investment range seeks to lead investing rounds making an initial investment of up to  million ideally at the formative stage of company development year established   arch venture partners city cities where offices are located chicago austin tx seattle san francisco dublin fund size and status nearly  billion under management across seven funds current fund  million arch venture fund vii closed  current biopharma portfolio companies achaogen acylin therapeutics agios pharmaceuticals allozyne alnylam pharmaceuticals array biopharma bind biosciences bluebird bio chiasma ensemble therapeutics fate therapeutics genvec groove biopharma hua medicine ikaria illumina isb accelerator kythera biopharmaceuticals lycera neurogesx nura omeros oncofactor permeon biologics phaserx pulmatrix receptos sorbent therapeutics syros pharmaceuticals theraclone sciences vbi vaccines ventirx pharaceuticals vlst xenoport xori typical investment range investment average or range percompany unavailable firm applies innovation investment model that invests conservatively in a seed round and then leads and coleads additional rounds to liquidity year established  as notforprofit arch development corp by university of chicago  burrill  co city cities where offices are located san francisco fund size and status  billion under management across seven funds current fund  million burrill capital fund iv closed for second time  current biopharma portfolio companies adlyfe catalyst biosciences captaris therapeutics cerca inights chromatin lightsciences oncology logical therapeutics neos therapeutics neurotech newbridge pharmaceuticals nora therapeutics odyssey thera scynexis sentinext therapeutics waterstone pharmaceuticals xdx typical investment range average funding  million to  million over the life of a company most investments are expected to be in the startup through mezzanine stages the largest number of investments are targeted to series a and b rounds the firm does invest in public entities principally invests in the united states and europe but has strategic interests globally year established   versant ventures city cities where offices are located menlo park ca newport beach ca san francisco basel switzerland vancouver bc fund size and status  billion in committed capital across four funds disclosed plans in october  to raise a  million fifth fund current fund  million versant venture capital iv lp closed  current biopharma portfolio companies am ventures achaogen audentes therapeutics biotie therapies cymabay therapeutics formerly metabolex flap flexion therapeutics fluidigm gensight biologics groove biopharma formerly mirina immune design inception  inception  inception  novira therapeutics opgen panmira pharmaceuticals phaserx quanticel pharmaceuticals ruiyi spark diagnostics theraclone sciences vlst typical investment range initial investments have started at  total investments have been as large as  million year established   healthcare ventures city cities where offices are located cambridge ma fund size and status  billion under management across nine funds current fund  million healthcare ventures ix lp closed  current biopharma portfolio companies aciex adheron therapeutics anchor therapeutics anexon apellis pharmaceuticals apofore bikam pharmaceuticals catalyst biosciences cleveland heartlab decimmune therapeutics dekkun galleon pharmaceuticals gitr globeimmune infacare pharmaceutical mosaic biosciences nanomr pathogenetix pharmathene promedior proteostasis therapeutics radius health seahorse bioscience shape pharmaceuticals stemgent synovex tensha therapeutics tetralogic pharmaceuticals theraclone sciences threshold pharmaceuticals trevena vaxinnate vaxxas xencor typical investment range up to  million total investment to achieve human proofofconcept invest predominantly in late preclinical and early clinicalstage focused companies with the goal of advancing a single product to human proofofconcept and exit through sale to a pharmaceutical or biotechnology company year established   bay city capital city cities where offices are located san francisco fund size and status  billion in capital commitments across five general life sciences vc funds and three vc funds targeting specific geographies or sectors of the life sciences current general lifesci vc fund  million bay city capital fund v closed in  most recent sector fund is decheng capital china life sciences usd fund i current biopharma portfolio companies aciex aviir braincells cadence pharmaceuticals civitas therapeutics conatus pharmaceuticals cydan cymabay therapeutics formerly metabolex dermira epizyme hyperion therapeutics intarcia therapeutics interleukin genetics itc nexus madrigal pharmaceuticals merus biopharmaceuticals nabsys poniard pharmaceuticals pharmakea therapeutics presidio pharmaceuticals ptc therapeutics reset therapeutics sunesis vivaldi biosciences typical investment range investment average or range percompany unavailable typically serves as lead or colead investor year established   advanced technology ventures city cities where offices are located palo alto ca and boston fund size and status  billion under management across eight funds current fund  million atv fund viii closed  current biopharma portfolio companies acceleron pharma calithera biosciences catabasis pharmaceuticals five prime therapeutics hydra biosciences portola pharmaceuticals second genome thrasos therapeutics verastem typical investment range investment average or range percompany unavailable year established     » notes figures converted to us dollars via wwwxecom on november   plans for versant venture capital v were disclosed in an october  form d filing with us securities and exchange commission see httpwwwsecgovarchivesedgardataxslformdxprimarydocxml see morgenthaler ventures has a new fund… and a new name fortune september  httpfinancefortunecnncomtagmorgenthalerventure reuters pe hub attributed the report to an unnamed source see essex woodlands seeks  mln for ninth fund httpwwwpehubcomessexwoodlandsseeksmlnninthfund see “highland capital partners establishes  million leap fund™ fuels businesses based on leap motion technology june  press release httpwwwhcpcomhighlandcapitalpartnersestablishesleapfund fortune on october  reported that highland closed on fund ix after securing  million in capital commitments see httpfinancefortunecnncomexclusivehighlandcapitalraisesmillionfund see form d filed april  httpwwwsecgovarchivesedgardataxslformdxprimarydocxml ×  november   pm   comments share get news first profit faster with benzinga professional get unlimited access to all content plus realtime newsfeed realtime audio news full calendar suite chat with our news desk recent pro alerts if unconventional tools are used as a substitute for rate hikes how does fx respond via forexlive pm  july   forexlive americas fx news wrap usd ends the week weak via forexlive pm  july   dynavax shares resume trade up  pm  july   postedin news insider trades   benzingacom benzinga does not provide investment advice all rights reserved   related articles crsp  stocks moving in wednesdays premarket session  stocks moving in mondays premarket session view the discussion thread newsletter  alerts become a wallstreet wizard market in  minutes everything you need to know about the market  quick  easy daily analyst rating a summary of each day’s top rating changes from sellside analysts on the street fintech focus yesterday’s biggest gainers and losers as well as  stocks to keep an eye on for today terms  conditions thank you for registering for benzinga’s newsletters and alerts • the daily analysts ratings email will be received daily between am and am • the market in  minutes email will be received daily between am and am • the fintech focus email will be received every friday between pm and pm if you have any questions as it relates to either of the three newsletters please feel free to contact us at zing sign up for email alerts on crsp trending recent  cld bbu  stocks moving in thursdays premarket session  mrk azn why is astrazeneca sinking today  x sbux  stocks moving in fridays premarket session  fb tsla the jpmorgan midday note that might have sent th  tsla teslas breakout will take longer but wi  ea intc earnings scheduled for july    x stld trump comments on trade caused  dvax dynavax gets  fda vote for hepatitis b vaccine  algn inside align technologys q beat and raise teen segment could see  nvda kn benzingas option alert recap from july   pfe atvi earnings watch apple tesla pfizer activisionblizza   things you may not know about anthony scaramucci  dcth nvax we spoke with the experts and learned the se  lmat imgn midafternoon market update cybero view upcoming earnings ratings dividend and economic calendars benzinga is a fastgrowing dynamic and innovative financial media outlet that empowers investors with highquality unique content popular channelsanalyst ratings be your own boss etfs economics forex hot news options press releases startups tech tools  featuresaffiliate program premarket prep feeds news widget real time feed sitemap submit news tips about benzingaabout us licensing and apis apps ios and android fintech awards blog syndication in the news careers service status contact us disclaimer privacy policy terms and conditions benzinga partners    zing  copyright benzinga cliffs sees  insider buys since earnings slump semiconductor ma activity for  may be second to only